Literature DB >> 21245658

Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines.

Daniel Mitchell1, Michelle Yong, Jyothy Raju, Nicole Willemsen, Matthew Black, Amanda Trent, Matthew Tirrell, Colleen Olive.   

Abstract

Considerable success has been made with many peptide antigen formulations and it appears that peptide-based vaccines are emerging as the next generation of prophylactic and remedial immunotherapy. However, peptides are typically poorly immunogenic and rely on delivery with potent immunostimulatory adjuvants that activate the innate and adaptive arms of the immune system. Our research aims to develop novel peptide antigen delivery systems that incorporate multiple pattern-recognition receptor (PRR) agonists and is focused on those designed to stimulate Toll-like receptors (TLRs) on dendritic cells (DCs). The cytokine (IL-4, IL-6, IL-10, IL-12 and IL-23) profiles of DCs induced by individual TLR agonists have been evaluated. From this data we predicted which TLR agonists may influence a particular T helper cell (Th) response. Using purified DCs that were derived from precursor cells in murine bone marrow and then stimulated simultaneously with multiple TLR agonists, we have shown synergy between various TLR agonist pairs leading to enhanced cytokine production. Using various mitogen-activated protein kinase (MAPK) inhibitors (c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) and p38 MAPK) we have demonstrated the importance of p38 MAPK and ERK signaling pathways in IL-12p70 and IL-12p40 production in DCs induced by TLR stimulation, whereas the JNK pathway appeared to have a negative regulatory role on cytokine production in DCs stimulated with certain TLR agonists. An important role for nuclear factor-kappa B and phosphoinositol-3-kinase as positive regulators of TLR signaling in DCs leading to cytokine production was also demonstrated. The significance of this research lies not only in improving potency, but by understanding the immunological mechanisms of adjuvanticity, in being able to tailor peptide vaccines to generate specific types of Th responses required for immunity against various types of pathogens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245658     DOI: 10.4161/hv.7.0.14567

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  5 in total

Review 1.  Nanoparticles and direct immunosuppression.

Authors:  Terrika A Ngobili; Michael A Daniele
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

Review 2.  Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Authors:  Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman
Journal:  Expert Rev Vaccines       Date:  2015-03-18       Impact factor: 5.217

3.  A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates.

Authors:  Neal N Padte; Mar Boente-Carrera; Chasity D Andrews; Jenny McManus; Brooke F Grasperge; Agegnehu Gettie; Jordana G Coelho-dos-Reis; Xiangming Li; Douglass Wu; Joseph T Bruder; Martha Sedegah; Noelle Patterson; Thomas L Richie; Chi-Huey Wong; David D Ho; Sandhya Vasan; Moriya Tsuji
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

4.  Saccharomyces cerevisiae mannan induces sheep beta-defensin-1 expression via Dectin-2-Syk-p38 pathways in ovine ruminal epithelial cells.

Authors:  Xin Jin; Man Zhang; Gui-Fang Cao; Yin-Feng Yang
Journal:  Vet Res       Date:  2019-02-04       Impact factor: 3.683

5.  Modulation of Innate Immune Responses via Covalently Linked TLR Agonists.

Authors:  Janine K Tom; Emmanuel Y Dotsey; Hollie Y Wong; Lalisa Stutts; Troy Moore; D Huw Davies; Philip L Felgner; Aaron P Esser-Kahn
Journal:  ACS Cent Sci       Date:  2015-10-28       Impact factor: 14.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.